Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at Wells Fargo & Company

Jazz Pharmaceuticals (NASDAQ:JAZZ) was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating in a note issued to investors on Thursday,Briefing.com Automated Import reports. The brokerage currently has a $170.00 price objective on the specialty pharmaceutical company’s stock, up from their prior price objective of $130.00. Wells Fargo & Company‘s price target indicates a potential upside of 25.52% from the company’s previous close.

Several other research firms have also recently weighed in on JAZZ. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. TD Cowen reduced their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Robert W. Baird increased their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Buy” and a consensus target price of $180.33.

Jazz Pharmaceuticals Stock Up 4.2 %

Jazz Pharmaceuticals stock opened at $135.44 on Thursday. The stock has a market cap of $8.19 billion, a PE ratio of 19.08, a P/E/G ratio of 0.92 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock’s fifty day moving average is $122.97 and its two-hundred day moving average is $116.89. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $136.55.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 5,053 shares of company stock valued at $617,442. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of JAZZ. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $25,000. Quadrant Capital Group LLC lifted its position in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. CoreFirst Bank & Trust acquired a new stake in Jazz Pharmaceuticals in the fourth quarter valued at about $28,000. Allianz SE purchased a new stake in Jazz Pharmaceuticals in the 4th quarter valued at approximately $29,000. Finally, Jones Financial Companies Lllp increased its position in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 130 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.